Volasertib for AML

Clinical use and patient consideration

Zhonglin Hao, Vamsi Kota

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients.65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy.

Original languageEnglish (US)
Article numberA205
Pages (from-to)1761-1771
Number of pages11
JournalOncoTargets and Therapy
Volume8
DOIs
StatePublished - Jul 17 2015

Fingerprint

Acute Myeloid Leukemia
Phase III Clinical Trials
Induction Chemotherapy
Cytarabine
Proxy
Compliance
Mortality
Population
BI 6727
Therapeutics

Keywords

  • Acute myeloid leukemia
  • Induction
  • Management
  • Volasertib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Volasertib for AML : Clinical use and patient consideration. / Hao, Zhonglin; Kota, Vamsi.

In: OncoTargets and Therapy, Vol. 8, A205, 17.07.2015, p. 1761-1771.

Research output: Contribution to journalReview article

@article{890d4c3ad72a459ebe67b3530598e160,
title = "Volasertib for AML: Clinical use and patient consideration",
abstract = "Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients.65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy.",
keywords = "Acute myeloid leukemia, Induction, Management, Volasertib",
author = "Zhonglin Hao and Vamsi Kota",
year = "2015",
month = "7",
day = "17",
doi = "10.2147/OTT.S60762",
language = "English (US)",
volume = "8",
pages = "1761--1771",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Volasertib for AML

T2 - Clinical use and patient consideration

AU - Hao, Zhonglin

AU - Kota, Vamsi

PY - 2015/7/17

Y1 - 2015/7/17

N2 - Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients.65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy.

AB - Acute myeloid leukemia (AML) is a disease diagnosed mostly in patients.65 years of age. Despite its heterogeneous nature, the different types of AMLs are still managed by standard induction chemotherapy for those who can tolerate it in the beginning. For the elderly and infirm patients, however, this approach leads to unacceptably high induction mortality rate. This article reviews past and current efforts searching for low-intensiveness treatments for the elderly and infirm patients who cannot tolerate the standard induction regimen. Volasertib, currently in Phase III clinical trials in combination with cytarabine, is reviewed as a promising agent for this patient population with AML, from the viewpoints of potential compliance and efficacy.

KW - Acute myeloid leukemia

KW - Induction

KW - Management

KW - Volasertib

UR - http://www.scopus.com/inward/record.url?scp=84937691645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937691645&partnerID=8YFLogxK

U2 - 10.2147/OTT.S60762

DO - 10.2147/OTT.S60762

M3 - Review article

VL - 8

SP - 1761

EP - 1771

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

M1 - A205

ER -